Macmillan Cancer Support and Prostate Cancer Research are pooling NHS records and patient experiences to widen how prostate cancer data informs care. The partnership expands Prostate Progress, a program that targets early diagnosis, personalized care and healthcare inequalities.
How prostate cancer data will shape services and policy
Prostate Cancer Research developed Prostate Progress to combine NHS health records with the lived experiences of people with cancer. Macmillan, one of the world’s leading cancer charities, will now help expand its reach.
The charities plan to use patient insights to inform advocacy, service design and policy. In addition, they aim to generate evidence on gaps, delays and variation in cancer pathways.
As a result, the program should show where improvements would have the greatest impact. It should also strengthen engagement with underserved communities.
Charity leaders outline the partnership
Peter Harrison, director of partnerships at Prostate Cancer Research, said health systems often miss the full picture. He argued that combining clinical data with patient experience closes that gap.
“By combining clinical data with the experiences people share about living with cancer, we can gain a much deeper understanding of where the system is working well, where it is falling short, and what needs to change,” Harrison said.
Harrison added that the partnership aims to build foundations for long-term improvements in cancer care. Those include reducing inequalities and supporting earlier diagnosis.
Claire Taylor, chief nursing officer at Macmillan, said patient voices strengthen the case for change. She also said the charity wants to learn what it is really like to live with prostate cancer, and to shape better services for people living with cancer.
“At Macmillan, we know that people living with cancer are the experts in their own lives, and when their experiences are heard alongside clinical data, we can build a far stronger case for change,” Taylor said.
AI tools add to prostate diagnosis efforts
Meanwhile, the National Institute for Health and Care Excellence has recommended five AI technologies for use in the NHS. The tools help doctors spot prostate cancer more accurately on MRI scans.
They include Pi, an AI tool developed by Lucida Medical. Up to 15 NHS hospitals are trialing it as part of the NHS Cancer Programme Innovation Open Call.
Looking ahead, Prostate Progress will explore new ways to use patient experience and clinical data together. The charities say the goal is more proactive and personalized care.

